BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12099074)

  • 21. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 22. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis.
    Yazici Y; Erkan D; Lockshin MD
    Clin Exp Rheumatol; 2000; 18(6):732-4. PubMed ID: 11138337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Etanercept].
    Mühlhäuser U; Münzel F; Eschenhagen T
    Dtsch Med Wochenschr; 2003 Aug; 128(34-35):1775-8. PubMed ID: 12934172
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.
    Mikhail M; Weinberg JM; Smith BL
    Arch Dermatol; 2008 Apr; 144(4):453-6. PubMed ID: 18427038
    [No Abstract]   [Full Text] [Related]  

  • 25. Etanercept, anticytokines and mania.
    Kaufman KR
    Int Clin Psychopharmacol; 2005 Jul; 20(4):239-41. PubMed ID: 15933486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C; Manger B
    Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept.
    van Luijn JC; Danz M; Bijlsma JW; Gribnau FW; Leufkens HG
    Scand J Rheumatol; 2011 May; 40(3):183-91. PubMed ID: 20858147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marked hypertriglyceridemia upon treatment with etanercept.
    Haroon M; Devlin J
    Joint Bone Spine; 2009 Oct; 76(5):570-1. PubMed ID: 19303341
    [No Abstract]   [Full Text] [Related]  

  • 29. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
    Lehnen M; Goos M; Dissemond J
    Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
    [No Abstract]   [Full Text] [Related]  

  • 30. The diagnosis and management of psoriatic arthritis in a professional football player presenting with a knee effusion: a case report.
    Brophy RH; MacKenzie CR; Gamradt SC; Barnes RP; Rodeo SA; Warren RF
    Clin J Sport Med; 2008 Jul; 18(4):369-71. PubMed ID: 18614892
    [No Abstract]   [Full Text] [Related]  

  • 31. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
    Pomerantz RG; Mody E; Husni ME; Qureshi AA
    J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
    Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
    Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
    [No Abstract]   [Full Text] [Related]  

  • 33. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
    Koó E; Brodszky V; Péntek M; Ujfalussy I; Nagy MB; Gulácsi L
    Orv Hetil; 2006 Oct; 147(41):1963-70. PubMed ID: 17120686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis.
    Besada E; Njålla RJ; Nossent JC
    Rheumatol Int; 2013 Oct; 33(10):2687-9. PubMed ID: 22886470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
    Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
    Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of rheumatoid arthritis with etanercept.
    Genovese MC; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment.
    Lories RJ; Derese I; Luyten FP; de Vlam K
    Clin Exp Rheumatol; 2008; 26(1):96-102. PubMed ID: 18328153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.
    Linardaki G; Katsarou O; Ioannidou P; Karafoulidou A; Boki K
    J Rheumatol; 2007 Jun; 34(6):1353-5. PubMed ID: 17552060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection.
    Rokhsar C; Rabhan N; Cohen SR
    J Am Acad Dermatol; 2006 Feb; 54(2):361-2. PubMed ID: 16443079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.